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Introduction
Patients with type 2 diabetes have a high risk to develop micro-and macrovascular complications. 1 Insulin resistance, which drives hypertension, glucose intolerance, endothelial dysfunction, dyslipidemia and a proinflammatory state, is generally considered to be of major importance in the pathophysiology of type 2 diabetes and cardiovascular complications. A therapeutic strategy that targets insulin resistance in type 2 diabetes may have beneficial effects on the cardiovascular risk.
Thiazolidinediones (TZDs) are a class of oral anti-hyperglycemic agents that can improve insulin resistance. TZDs such as pioglitazone and rosiglitazone are ligands for peroxisome proliferator-activated receptors (PPARs), in particular PPAR-γ. These nuclear transcription factors are involved in glucose homeostasis, lipid and lipoprotein metabolism and adipogenesis. TZDs improve glycemic control by increasing insulin sensitivity and have also been shown to favorably modulate other components of the metabolic syndrome. 2 In addition, pparγ-agonists may have direct effects on vessel wall structure, inflammation and endothelial function.
Endothelial dysfunction, metabolic abnormalities related to insulin resistance and a proinflammatory state, are characteristic of patients with type 2 diabetes. Endothelial dysfunction is characterised by decreased availability of endotheliumderived nitric oxide (NO) and can be assessed clinically by impaired vasoreactivity of the brachial artery after an ischemic stimulus with flow-mediated dilation. 3 Previous studies showed already improvement of endothelial vasoreactivity in insulin resistant patients (obesity, polycystic ovary syndrome and type 2 diabetes) with TZD treatment. However many studies were done with troglitazone, now withdrawn from the market, and/or with long treatment periods. [4] [5] [6] [7] In a non-randomised, open-label study, pioglitazone treatment for 3 months resulted in improvement of endothelial function in type 2 diabetic patients. 8 In this study pioglitazone treatment also significantly reduced the metabolic abnormalities associated with type 2 diabetes. To tease out a direct vascular effect on vascular function of pioglitazone from its indirect metabolic effects we studied, double blind and crossover, the direct vascular effect of short-term (4 weeks) treatment with pioglitazone on endothelial function in patients with type 2 diabetes.
Chapter 4

Subjects and methods
Subjects
Twenty male, non-smoking patients with type 2 diabetes were recruited. All patients were treated with oral anti-hyperglycemic agents (9 patients with sulphonylurea derivates, 4 patients with metformin and 7 patients with a combination of metformin and sulphonylurea derivates) which continued during the study. Subjects with poor glycemic control (HbA1c> 9%) were not included. Other relevant exclusion criteria were presence of macro-or microvascular disease and use of vasoactive medication (e.g. beta-blockers, calcium entry blockers, ACE-inhibitors, angiotensin type 1 receptor blockers, statins, aspirin, non-steroidal inflammatory drugs). The protocol was approved by the ethical review board of the University Medical Center Utrecht (UMCU). All subjects gave written informed consent. Measurements were carried out in accordance with local institutional guidelines in a Good Clinical Practice-certified unit.
Study design
The study was designed as a prospective, randomised, crossover, placebo-controlled, double blind trial. Patients eligible to take part in the study were randomised to receive pioglitazone 30 mg once daily (Eli Lilly, Indianapolis, U.S.A.) or placebo for 4 weeks in addition to their oral anti-hyperglycemic agents. Forearm vascular function was performed after four weeks followed by a washout period of six weeks. Crossover of therapy occurred at the end of the washout period with reanalysis of vascular function at 4 weeks. At the beginning and at the end of each 4-week treatment period laboratory parameters were determined. Patients were instructed to fast for at least 10 hours prior to the tests. No study medication or other medication was used on the morning of the study days.
Methods
Assessment of vascular function
Experiments were performed in a temperature-controlled room (22-24°C) in the morning. Vascular function tests after pioglitazone and placebo treatment were performed at the same time for each individual in order to exclude daytime variability. Upon arrival after an overnight fast, patients were asked to rest ina supine position for 20 minutes before ultrasonographic assessment of post-ischemic flow-mediated vasodilation (FMD) of the brachial artery. This procedure was followed by blood withdrawal for laboratory measurements.
For assessment of post-ischemic NO-dependent FMD of the brachial artery, ultrasound measurements were performed at the elbow of the right arm using a vessel wall-movement system (Wall Track System, Pie Medical) that consists of a 10 MHz linear array transducer connected to a data acquisition system and a personal computer. 9 In order to optimize quality of the ultrasound images of the arterial wall, ultrasound gel, a 200 ml water bag (as conductive medium), and a fixed probe holder were used. An optimal two-dimensional B-mode image of the brachial artery was obtained. An M-line perpendicular to the vessel was selected and the ultrasound system was switched to M-mode. The vessel-movement detector system registers the end-diastolic vessel diameter repeatedly during a period of 12 seconds. The first three measurements were averaged to provide a baseline arterial diameter. By inflation of a blood pressure cuff for 5 minutes at a pressure of 200 mmHg, ischemia was applied to the forearm distal to the location of the transducer. Ultrasonographic measurements continued for 4 minutes after cuff release at 30-second intervals. The widest lumen diameter was taken as a measure for maximal post-ischemic vasodilation. In eight patients sublingual nitroglycerine spray (400µg) was administered after a 15-minute rest in order to allow the arterial diameter to return to its baseline value. After 2, 3, 4 and 5 minutes the vasodilatory respons to nitroglycerine was assessed as previously described. FMD and nitroglycerine-induced vasodilation were calculated as the percentage change relative to the baseline diameter.
Laboratory assessment
Fasting blood was drawn and plasma was frozen at -20°C until further analysis. Glucose, creatinine, serum alanine transferase (ALT), serum aspartate transferase (AST), total cholesterol, triglycerides and high-density lipoprotein cholesterol (HDL-C) were measured by standard enzymatical laboratory methods (Vitros 250; Johnson/Johnson). Low-density lipoprotein cholesterol (LDL-C) was calculated with the Friedewald formula. HbA1c and free fatty acids (FFA) were photometrically performed (Hitachi 911; Roche). Insulin levels were determined with an immunological method (Immulite 2000; Diagnostic Prod Corp.). Measurements of plasma adiponectin, interleukin-6 (IL-6) and high-sensitive C-reactive protein (hs-CRP) were performed with a commercially available kit (ELISA; R&D Systems Inc.).
Statistical analysis
Results from vascular function tests and laboratory analysis are expressed as mean + standard error. Differences in FMD and metabolic parameters between pioglitazone and placebo treatment were analysed with a paired t-test (95% confidence interval). In case of non-normal distribution the Wilcoxon Signed Rank test was used. Statistical Chapter 4 significance was taken at the 5% level. Correlations between the change in FMD and the change in metabolic or inflammatory parameters were analysed by linear regresion.
Results
All subjects completed the study. The demographic, clinical and laboratory characteristics are shown in Table 1 . No carry-over effects between the two treatment periods were observed for any parameter. A significant increase in adiponectin plasma levels was observed during pioglitazone treatment compared to placebo after only 4 weeks (3948±573 vs. 7591±953 ng/ml, p=0.002). Furthermore a significant decrease in CRP concentration was observed during pioglitazone treatment compared to placebo after only 4 weeks (3.5±0.6 vs. 2.6±0.5 mg/l, p=0.01) while IL-6 plasma concentrations did not change significantly.
We did not observe a difference in the effects of pioglitazone between patients using metformin or a combination of metformin and sulphonylurea derivates and the group of patients only treated with sulphonylurea derivates (data not shown). No change in weight or blood pressure was observed during pioglitazone treatment. Fasting glucose concentrations and lipids were not different between the pioglitazone and placebo treatment periods. Edema did not occur in any patient on pioglitazone treatment. Pioglitazone treatment was not associated with liver enzyme abnormalities.
Effects of pioglitazone on brachial artery vasoreactivity
The baseline arterial diameter was similar during pioglitazone and placebo treatment (Table 3) . Table 3 . Ultrasound assessment of brachial artery vasoreactivity Flow-mediated vasodilation (FMD) was significantly increased by pioglitazone (3.08±0.53% vs. 5.38±0.46, p=0.001) ( Table 3) . As ultrasound recordings of the post-ischemic arterial diameter were performed every 30 seconds during 5 minutes in our protocol, a difference between post-ischemic vasoreactivity at all time points between pioglitazone and placebo treatment could be observed (Figure 1 ). There were no significant differences in the effects of pioglitazone between the group of patients using metformin or a combination of metformin and sulphonylurea derivates and the group of patients only treated with sulphonylurea derivates. Nitroglycerin-induced endothelium-independent vasodilation of the brachial artery was not significantly different between both treatments (12.04±1.09% vs. 14.49±1.36, p=0.09) indicating that there seemed to be no alteration of large vessel vascular smooth muscle cell (VSMC) responsiveness to NO (Table 3) .
Correlation between endothelial function, metabolic and inflammatory changes
We used a study-design with short-term pioglitazone treatment to avoid known long-term metabolic improvement of insulin sensitivity to investigate direct vascular effects of pioglitazone. Although already after treatment for 4 weeks, significant beneficial changes in insulin, free fatty acids, adiponectin and CRP were observed in our study no correlation was present between the beneficial changes in insulin, FFA, adiponectin or CRP, and the improvement of FMD (Figure 2) .
Discussion
In the current study we demonstrate that short-term pioglitazone treatment ameliorates endothelial dysfunction in conduit arteries irrespective of significant beneficial changes in plasma levels of insulin, FFA, adiponectin or CRP in type 2 diabetics.
To tease out metabolic effects from direct vascular effects we aimed to study relatively short-term actions of pioglitazone rather than long-term effects. Longterm TZD treatment has been shown to significantly change body composition and to have profound effects on the glycemic and lipid profile. The first metabolic effects were found as early as the 2-4th week of therapy but maximal decreases occurred after 10-14 weeks [10] [11] [12] . Most clinical studies observed substantial improvements in metabolic parameters by TZDs after 8-or more weeks of treatment. 13 These longterm anthropometric and metabolic alterations are likely to significantly modulate vascular function and inflammatory parameters. Using a 4-week treatment period we did not observe significant differences in fasting lipids and glucose between the pioglitazone and placebo treatment period. Nevertheless, insulin, FFA, adiponectin and CRP concentrations were beneficially changed already. No relation was found between the changes in insulin, FFA, adiponectin or CRP, and the improvement of FMD. However, in view of the limited number of patients studied, such a relation can also not be entirely excluded.
Our results are in line with previous studies showing antiatherogenic effects of pioglitazone in type 2 diabetic patients independent of its antidiabetic effect. 8, 14 An explanation could be the direct effects on the vascular wall of TZDs. PPAR-γ mRNA is expressed in endothelial and vascular smooth muscle cells. 15 TZDs increase NO release from endothelial cells without altering expression of endothelial nitric oxide synthase. 16 A direct effect on NO availability by pioglitazone may have contributed to the increase in FMD.
Other direct effects of pioglitazone on vascular smooth muscle cells in vitro have also been observed. These actions include attenuation of vasoconstriction as well as inhibition of L-type Ca 2+ currents in VSMC. 17, 18 In order to study vascular smooth muscle responsiveness to NO we administered nitroglycerin, a nitric oxide donor, before ultrasound assessment of brachial artery diameter. No significant difference was observed in endothelium-independent vasodilation between placebo and pioglitazone treatment indicating that pioglitazone does not seem to alter large vessel VSMC responsiveness to NO.
Interestingly, pioglitazone also significantly decreased C-reactive protein (CRP) after only four weeks of therapy. Concentrations of CRP are increased in patients with type 2 diabetes. This is considered to reflect a low-grade inflammatory state that is likely to contribute to the increased cardiovascular morbidity and mortality in patients with type 2 diabetes. CRP concentrations correlate with several components of the metabolic syndrome 19 and CRP is considered a strong predictor of cardiovascular events. Our results are in accordance with a study by Haffner et al. who showed a reduction in CRP after 26 weeks of treatment with another TZD, rosiglitazone. 20 Although our data suggest no major role for adiponectin, FFA or insulin in improvement of conduit artery endothelial function during pioglitazone, the sample size is a limiting factor to more reliably assess the possible existence of a relationship between these parameters and endothelial function. An increase in adiponectin by pioglitazone has previously been shown 8 and adiponectin can directly stimulate NO production by phosphorylating eNOS by AMP-activated protein kinase in endothelial cells in vitro. 21 High levels of FFA impair NO production by generation of reactive oxygen species (ROS). 22 In addition, FFA decrease insulin sensitivity in peripheral tissues. We included subjects who were only using oral anti-hyperglycemic agents. Since insulin could have profound effects on the vasculature, caution should be taken to extrapolate our results to patients with type 2 diabetes who use combination treatment consisting of pioglitazone and insulin. In addition, our patients did not use vasoactive medication. Many patients with type 2 diabetes use pharmacologic agents such as angiotensin-converting enzym blockers, angiotensin-II antagonists and statins improve endothelial function. It remains to be determined whether pioglitazone has additional benefits on endothelial function in these patients.
In conclusion, 4-weeks pioglitazone treatment improves conduit artery endothelial function, independent of metabolic changes in patients with type 2 diabetes. This may contribute to decreased cardiovascular risk in these patients.
